Despite an 8% decline in quarterly net sales to $105 million compared to $113 million last year, American Vanguard experienced a notable 25% increase in net income. This was driven by a focus on higher-margin products, improved factory performance, and reduced operating and interest expenses. The company's gross margin as a percentage of sales increased from 37% to 39%, and underlying operating expenses decreased by 10%. Additionally, American Vanguard has strengthened its balance sheet by reducing inventory by $18 million and improving cash from operations by $38 million year-to-date. The company remains optimistic about the future, with plans to commercialize its SIMPAS prescription application technology in Q4, expand its core product portfolio, and introduce new herbicide and insecticide solutions.